Browse by Medical Category
Explore current research projects in the Department of Neurology or search our open clinical trials and medical research studies.
See all clinical trials and research studies
The Advanced Tissue Resource Center in the Department of Neurology at Massachusetts General Hospital serves as a molecular and anatomic neuropathology resource for the Boston neuroscience community. Our research incorporates advanced micro-molecular profiling technologies into studies of human neurodegenerative and psychiatric diseases.
Our research group is focused on risk estimation, treatment and prevention of age-related brain deterioration.
The Albers Laboratory uses the olfactory system of mice and humans to elucidate early pathologic events of neurodegeneration.
We take a multidisciplinary, basic science to clinic translational approach to designing patient-oriented experimental and clinical trials for aging, dementia, and other neurodegenerative disorders.
Dr. Andrew J. Cole’s interests as a research investigator include clinical trials, clinical neurology, epilepsy, and basic neuroscience research.
Brian Bacskai's laboratory uses sophisticated optical techniques to address fundamental questions in Alzheimer's disease research.
The BADR lab is focused on studying the genetic drivers of malignancy and treatment resistance as well as developing targeted and experimental therapeutics for brain tumors.
The research goal of Dr. Berezovska's lab is to study the cellular and molecular mechanisms of Alzheimer's disease pathology.
The Massachusetts General Hospital Biorepository for Neurological Injury advances research in brain health and recovery by providing data to help researchers understand how genes and other factors contribute to risk of brain disease, recovery from brain injuries and the maintenance of a healthy brain.
The laboratory combines gene expression profiling and chemical screening of novel cellular models to understand the pathogenesis of hereditary dystonias.
The Breakefield laboratory uses molecular genetic techniques to elucidate the etiology of inherited neurological diseases and to develop vectors which can deliver genes to the nervous system for therapeutic purposes.
The Mass General Center for Rare Neurological Diseases (CRND) aims to eradicate rare disorders of the nervous system by leveraging the power of biological insights towards design and implementation of clinical trials.
The Chemical Genomics Laboratory (CGL) is unraveling the molecular mechanisms underlying neuroplasticity to develop novel, targeted therapeutics for the treatment of neuropsychiatric and neurological diseases.
An international consortium of scientists, physicians and advocates working to advance research and clinical care for people with XDP.
Researchers in Brad Dickerson's Laboratory seek to understand the relationships between brain anatomy, physiology, and behavior in humans across the lifespan and in those with neurodegenerative diseases.
Marian M. DiFiglia, PhD, is investigating the role of the HD mutation in the molecular and cellular events leading to neurodegeneration.
Dr. Florian Eichler's lab studies monogenetic lipid metabolism disorders of the nervous system at the Massachusetts General Hospital and Harvard Medical School.
The Delirium Lab at Massachusetts General Hospital is committed to determining the causes and treatments of delirium through a combination of translational and clinical research.
The Familial Dementia Neuroimaging Lab is focused on the study of age-related cognitive and brain changes that may predispose individuals to develop dementia later in life
Alice W. Flaherty, MD, PhD, has a dual appointment as associate professor of neurology, and of psychiatry at Harvard Medical School.
“Development and characterization of animal models of human neurodegenerative diseases...”
The Functional Neurology Research Group at Massachusetts General Hospital, led by David Perez, MD, aims to identify biomarkers of disease, prognosis and treatment response for Functional Neurological Disorders.
The Global Neurology Research Group, part of the Department of Neurology and the Neurological Clinical Research Institute, finds innovative solutions to improve the quality of neurological care in low- and middle-income countries.
Dr. Glykys studies how seizures are generated in the pediatric brain and how we can enhance the brain’s inhibition system to treat seizures.
Dr. Gomez-Isla investigates the neurobiology of normal aging, Alzheimers, and other dementias.
The Gomperts lab investigates Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease
Research on the pathogenesis, diagnosis and treatment of cerebral amyloid angiopathy (CAA), a cause of cerebral hemorrhage in the elderly.
Led by Dr. Hersch, the Laboratory investigates Huntington’s disease using transgenic mouse models and human brain tissue. Research also includes HD clinical trials.
The Hyman lab focuses on research in neural system failure underlying cognitive loss in Alzheimer’s disease.
Molecular research of neurodegeneration in Alzheimer’s disease (AD) focused on identifying cellular pathways regulating the generation of the toxic beta-amyloid protein (Abeta).
Ksenia Kastanenka’s research interests lie in the sphere of aging with particular emphasis on Alzheimer’s disease. The laboratory is focused on studying circuitry disruption during the disease progression and mechanisms of action of Alzheimer’s therapeutics aimed at reversing the disease.
Our mission is to drive the development of new mechanism-driven therapies through a richer understanding of how neurologic disease affects behavior.
Dr. Brian Edlow’s Laboratory for NeuroImaging of Coma and Consciousness (NICC) aims to improve acute care and long-term outcomes for patients with coma and other disorders of consciousness caused by traumatic brain injury.
Clotilde Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) and to develop therapeutic strategies.
The MassGeneral Institute for Neurodegenerative Disease (MIND) is a research center for Alzheimer’s, ALS (Lou Gehrig’s), Huntington’s, Parkinson’s and other neurodegenerative diseases. The Institute's mission is to accelerate research discoveries that will lead to treatment and cures.
MIND Informatics develops and applies integrative computational methods in biomedical and brain research, working with leading clinicians and researchers to understand and cure neurological disorders.
The Clinical Proteomics Research Center explores neurovascular pathophysiology using a translational approach - with the goal of developing prognostic tools to guide clinical decision-making.
Dr. Robert Moir's research focuses on the biochemical and cellular mechanisms involved in neurodegeneration in Alzheimer's disease and aging.
We use established health services research methods to identify and compare alternative delivery models for achieving desired outcomes. We have a particular interest in strategies for reducing costs while improving the quality of care. The ultimate mission of our group is to design and implement coordinated care models for neurological care of high value.
The Multiple Sclerosis (MS) Imaging Laboratory in the Department of Neurology at Massachusetts General Hospital, led by Eric Klawiter, MD, Msc, is focused on developing new imaging techniques to better understand, diagnose and treat multiple sclerosis.
Dr. Swoboda’s research and clinical activities are dedicated to the diagnosis and treatment of neurologic disorders, especially neuromuscular diseases, movement disorders, and neurodegenerative disorders with childhood-onset.
The Neurological Clinical Research Institute (NCRI) at Mass General is experienced in designing, developing, facilitating, and conducting multicenter clinical trials in Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases.
Drs. Vaina and Buonanno's Neurology of Vision Lab links stroke neurology to neuroscience and multimodal brain imaging, to offer diagnosis and treatment of disorders of the brain affecting visual perception and cognition.
The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT ) consists of a Clinical Coordinating Center (CCC) at Massachusetts General Hospital, a Data Coordinating Center (DCC) at the University of Iowa, and 25 clinical sites throughout the country.
With faculty members from the departments of Neurology, Radiology, Pediatrics, and Anesthesia and Critical Care, the Neuroscience Center works to understand the biology of neurological disorders and develop novel methods of diagnosis and treatment.
The Pediatric Epilepsy Research Lab studies how neuronal ion transport and synaptic plasticity alter the spread of epileptic activity in neural networks.
The laboratory focuses on identifying common mechanisms that cause neurodegenerative disease in order to identify novel therapeutic targets.
The Salinas Lab is driven by the guiding hypothesis that our social relationships alter the biology of the brain and are crucial to brain health.
I am interested in the structure and function of the cerebellum, and in the cerebral and cerebellar roles in cognition and emotion. We perform neuroanatomical tract tracing studies in monkey; structural and functional MRI and PET in patients and controls; and we treat and study patients with ataxia and/or cognitive disorders.
The Schwarzschild lab targets three purines—adenosine, caffeine and urate—in pursuit of improved therapy for Parkinson’s and related neurodegenerative diseases.
We combine microelectrode and macroelectrode recording and computing techniques to study brain activity, mechanisms for brain machine interface, and the neurophysiology of epilepsy.
Bakhos Tannous, PhD – Research focus in molecular Imaging, gene transfer technologies and high throughput screening aiming at finding novel therapeutics against brain tumors.
TRANSCEND. Treatment Research and NeuroSCience Evaluation of Neurodevelopmental Disorders.
The Wainger Lab at Massachusetts General Hospital focuses on how abnormalities of motor and sensory neuron physiology contribute to diseases such as ALS and chronic pain.
The Walker Laboratory at Massachusetts General Hospital combines genetic, molecular and biochemical approaches to investigate neurofibromatosis type 1 (NF1) and schwannomatosis.
We study muscular dystrophies with the long-term goal of finding new treatments for patients.
STAT news profiles MGH investigator Robert Moir (pictured right), and quotes MGH co-investigator Rudolph Tanzi (pictured left). Learn more
Science Magazine covers promising study led by MGH investigators Se Hoon Choi, PhD (pictured left) and Rudolph Tanzi, PhD (pictured right). Learn more
Study conducted by Merit Cudkowicz, MD, Eric C. Klawiter, MD and the NeuroNEXT team shows promise for treating progressive multiple sclerosis. Learn more.
A new research study lead by MGH investigators Rudolph Tanzi, PhD (pictured left), and Robert Moir, PhD (pictured right) suggests there may be. Learn more
We are proud to be the Clinical Coordination Center for NeuroNext, under the leadership of our Neurology Department Chief Dr. Merit Cudkowicz and Marianne Chase. Learn more.
Congratulations to Alex Sherman, MD, and our very own NeuroBANK team at the NCRI for receiving the award for personalized and translational medicine! Learn more
Mass General Hospital Giving features a research breakthrough in understanding the cause of X-linked dystonia parkinsonism (XDP).Learn more
Dr. Merit Cudkowicz, Chief of Neurology at Mass General Hospital discusses innovations in ALS clinical trials since she started in the field in 1994. Learn more.
New Stem Cell Treatment Could Help People Suffering From ALS featured on CBS Boston. Learn more.
Scott Plotkin, MD, PhD, and Vijaya Ramesh, PhD, are using their respective expertise in clinical and fundamental science to investigate new treatments for neurofibromatosis and two related disorders. Learn more.
Mass General investigators such as Florian Eichler, MD, are demonstrating how a collaborative research approach that includes patients, clinicians, scientists and members of industry could dramatically improve the treatments available for rare disease patients. Learn more.
Congratulations to Brian Edlow, MD, Associate Director of our Center for Neurotechnology and Neurorecovery – his paper, “Early Detection of Consciousness in Patients with Acute Severe TBI,” was named one of the “Best of 2017” by Brain-A Journal of Neurology.
Back to Top